Answers are grounded in this paper and cite their sources.
Background Vascular endothelial growth factor receptor tyrosine kinase inhibitors (VEGFR-TKIs) are widely used in solid tumor therapy, accompanied by a high rate of dermatologic adverse events that severely disrupt treatment. However, their real-world characteristics and drug-specific differences remain unclear. Objective To analyze the characteristics of skin adverse events associated with 11 VEGFR-TKIs in the real world using the FDA Adverse Event Reporting System (FAERS) database, providing evidence for clinical safety management. Methods FAERS data from 2004 to 2025 were included. Signal detection was conducted using the ROR, PRR, IC, and EBGM, combined with demographic analysis, time to onset, and Weibull modeling. Results A total of 34,088 cases of skin adverse events were included, with hand-foot skin reaction (HFSR) being the most common signal. Sorafenib, cabozantinib, and vandetanib exhibited more pronounced toxicity signals. Some drugs presented specific manifestations: sunitinib with skin yellowing, pazopanib with hair color changes, and cabozantinib with skin ulceration. Most skin-related adverse events occurred early during treatment (within 4 weeks). Conclusion VEGFR-TKIs demonstrate both common and specific skin toxicities, which predominantly occur early and are associated with efficacy, providing real-world evidence to support individualized clinical monitoring and early interventions.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: